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Background: Epidemiological studies on genital human papilloma viruses infection (HPVs) in general population
are crucial for the implementation of health policy guidelines for developing the strategies to prevent the primary
and secondary cervical cancer. In different parts of Iran, there is a lack of population-based studies to determine the
prevalence of HPV in the general population. The aim of this population-based study is to compare the prevalence
rate of genital HPV infection among reproductive women with our previous clinic-based data, which showed a
prevalence rate of 5% in women in southern Iran.
Results: Using general primers for all genotypes of HPV, of 799 randomly selected women, five (0.63%,
95% CI 0.23-1.55%) tested positive for HPV DNA. Overall, seven different HPV genotypes were detected: six types
(16, 18, 31, 33, 51 and 56) were carcinogenic, or “high risk genotypes” and one genotype (HPV-66) was “probably
carcinogenic.”
Conclusions: In a population-based study, the prevalence of HPV infection among southern Iranian women was
lower than that observed worldwide. However, our gynaecological clinic-based study on the prevalence of HPV
infection showed results comparable with other studies in the Middle East and Persian Gulf countries. Since
gynaecological clinic-based data may generally overestimate HPV prevalence, estimates of prevalence according to
clinic-based data should be adjusted downward by the population-based survey estimates.
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Cervical cancer is an important public health problem
worldwide, especially in developing countries, where
more than 80 percent of the estimated global cases
occur [1,2]. Persistent infection by certain types of
human papillomavirus (HPV) is a principal risk for the
development of both high-grade cervical cancer precur-
sors and invasive cervical cancer [3,4].
Oncogenic HPV DNA is detected in more than 90 per-
cent of the cervical tissues of patients with cervical* Correspondence: keivanzandi@yahoo.com
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reproduction in any medium, provided the orcarcinoma or cervical intraepithelial neoplasia [5,6].
Worldwide, 70% of cervical cancers are due to oncogenic
HPV 16 and 18 genotypes [7]. In Iran, HPV infection is
prevalent in all categories of cervical neoplasia [8]. The
prevalence of HPV in cervical cancer in Iran was reported
to be similar to that in most countries of the world [9].In
southern Iranian patients with cervical cancer, more than
80% of samples were HPV DNA positive [10]. The HPV
type 16 was also the most common genotype found in
Iranian women with cervical cancer [9].
Most epidemiological data for HPV infection comes
from cross-sectional studies with samples taken from
women in different hospitals and gynecological clinics
[8-14]. These women had cervical neoplasia or cancer
[8-10], abnormal cervical cytology [11-13], and normal
Pap smears [10,11,14,15].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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oncogenic HPV types that potentially reduce the inci-
dence of cervical and other anogenital cancers, Data on
the HPV burden in the general population is essential to
strengthen the guidelines for the implementation of
health policy strategies for the prevention of primary
and secondary cervical cancer [16].
Therefore, we carried out The purpose of this
population-based study is to investigate the HPV burden
among women in southern Iran Since we are particularly
interested in understanding the level of and the differ-
ence in the prevalence of HPV infection between our
population-based study and our clinic-based data, we
compared the results of our previous clinic-based study
with those of the present study.
Methods
Community sampling, survey procedure and data
collection
This study was approved by the medical-ethical commit-
tee of Bushehr University of Medical Sciences.
A cross-sectional, population-based study was used to
select women of childbearing age (21–50 years old) from
Bushehr Port (the center of Bushehr province, an Iranian
province with the longest border on the Persian Gulf )
from November 2009 to May 2010.
Participants were an age-stratified random sample of
women aged 21 to 50 years. They were selected from 51
urban and 24 suburban areas in Bushehr Port. The first
cluster in each area was selected using a random num-
ber table. The sampling interval was added sequentially
to the random number to complete the selection of the
remaining clusters in each area. The total number of
women selected in each area was proportional to the
total number of childbearing women in that area.
Regarding our previous study on women who had rou-
tine Pap tests in Bushehr Port [12], it was estimated that
the prevalence of HPV infection in a population-based
setting was unlikely to exceed 5% (p = 0.05). With a con-
fidence level of 95% and absolute precision of 2 percent-
age points (d = 0.02) and using a simple random
sampling method, the sample size was estimated to be
around 456 women. By considering a design effect of 2
due to the cluster sampling strategy of the study, the
estimated sample size was doubled (n = 912 women).
Participants who were pregnant or menstruating at the
time of the tests were excluded. In Iranian-Islamic cul-
ture, sexual intercourse before marriage is forbidden.
Therefore, women who had never been married were
considered virgins and were also excluded.
The selected participants were informed about the study
through a letter distributed door-to-door by the survey
groups employed in the study. After briefing the respon-
dents to the letter with some basic information aboutcervical cancer and its associated risk factors, they were
invited to participate in the screening program at the Per-
sian Gulf Tropical Medicine Research Center at Bushehr
University of Medical Sciences.
All participants were asked to come to the survey
centre at 07:30 am and stay until 9:30 am. Upon their ar-
rival, information regarding age, marital status, educa-
tion, socioeconomic status, smoking, obstetrics history,
history of oral contraceptive usage, and sexually trans-
mitted diseases were recorded on a questionnaire used
by trained interviewers.
Written informed consent was obtained from the all
participants for publication of this report.
Based on national reports, 200,000 Tomans (200 US $)
income per month was defined as the line for poverty.
The women below the poverty line or in the range which
households could maintain a minimum standard of living
(200,000 to 450,000 Tomans income per month) were
considered to be in the low socioeconomic status.
Two separate samples were taken from the ectocervix
and endocervix using a wooden Ayre spatula (for cyto-
pathological exam) and endocervical cytobrush (for the
PCR test).
The Pap smear slides were immediately fixed with
ethanol and further processed for diagnosing by cyto-
pathologists. Bethesda System 2001 for reporting cer-
vical/endocervical/vaginal cytology (Pap smears) was
used (http://www.bethesda2001.cancer.gov). Cells show-
ing koilocytic change, multinucleation, and dyskeratosis,
with the addition of anucleate keratinised squamous
cells and keratinised squamous were considered cyto-
logical changes of HPV infection.
DNA extraction
The exfoliated cells on the cytobrush were suspended in
Tris-EDTA, and the suspension was centrifuged at
3000 g for 5 minutes. The supernant was removed, and
the cell pellet was re-suspended in 0.5 ml of Tris-EDTA
and then transferred to the sterile microotube. All sam-
ples were digested by lysis buffer containing proteinase
K, which was followed by extensive extraction with phe-
nol/chloroform [17]. The DNA quality was evaluated by
a PCR test using following primers: forward primer
PCO3: 50-ACACAACTGTGTTCACTAGC-30; reverse
primer PCO4: 50-CAACTTCATCCACGTTCACC-30.
These primers can amplify a 110 bp product from the
human β-Globin gene [18].
HPV PCR
β-Globin positive samples were subjected to HPV PCR
by forward primer GP5+: 50-TTTGTTACTGTGGTA
GATACTAC-30 and reverse primer GP6+:50-AAAAA
TAAACTGTAAATCATATTC-30 for L1 open reading
frame (ORF), which amplifies a 150 bp product from the
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in previous studies [12,17,18]. PCR was performed
according to the procedure described previously [18].
The DNA extracted from the HeLa cell line was used as
the HPV positive control and no DNA was added for
the negative control. Samples were subsequently sub-
jected to agarose gel electrophoresis.
HPV genotyping by reverse hybridization using the
INNO-LiPA HPV
Genotyping system
The DNA extracted from the HPV PCR positive samples
were subjected to genotyping using the INNO-LiPA
HPV genotyping system (INNOGENETICS N.V., Ghent,
Belgium) at the Keyvan Virology Laboratory, Tehran,
Iran. Briefly, the 28 oligonucleotide probes that recognize
25 different types (Table 1) were tailed with poly(dT) and
immobilized as parallel lines to membrane strips. The in-
terpretation for the HPV genotyping assay was performed
as described previously [19].
Statistical analysis
All statistical analyses were performed using the PASW
Statistics GradPack 18 (SPSS Inc., Chicago, IL).
Results
Characteristics of the studied population
A total of 799 women of reproductive age, 17 to 50 years,
were evaluated. The mean (± SD) age of women in the
study was 35.96 (± 8.08). Of 799 participants, 26.3%
were between 17 and 30 years, 36.5% were between 31
and 40 years, and 37.2% were between 41 and 50 years.
The educational level of 112 (15.07%) women was
elementary school, and 33 (4.44%) women were illiterate.
A total of 112 (15.07%) participants had low socioeco-
nomic status.
The majority of the studied population (98.7%) was
married. The mean age of first sexual intercourse (dur-
ing marriage) was 19.16 ± 3.97 years. None of the women
had a history of multiple sexual partners. The median
number of pregnancies was three for the studied popula-
tion. The history of tobacco smoking was found inTable 1 The prevalence of HPV DNA positivity and cervical cy
the type of study
Popu
PCR Positive for HPV DNA; n (%)
Pap test positive for HPV; n(%)
PCR and Pap Test Positive for HPV; n
Carcinogenic HPV genotypes 16,
Probably carcinogenic HPV genotypes
*Zandi et al. [12].14.4% of the women. A total of 464 (58.1%) women had
used oral contraceptive pills. However, 124 (15.5%) of
the studied population reported that they were current
users of oral contraceptives. The median duration of oral
contraceptive usage by the participants was three years.
Previous sexually transmitted disease was reported by
44 (5.5%) women. However, 11 (1.4%) women reported a
positive history of previous sexually transmitted disease
via their husbands. Of the studied population, 375
(46.9%) had never had a Pap test.
HPV DNA PCR and genotyping
Using general primers for all genotypes of HPV, of 799
tested samples by PCR, five (0.63%, 95% CI 0.23-1.55%)
women were positive for HPV DNA.
Genotyping of the PCR positive samples revealed that
two women were infected with more than one genotype
(one of them infected with genotypes 16, 56 and 66, and
the other one infected with genotypes 31 and 33). The
other three patients were infected with one genotype of
HPV (16, 51 or 18). Therefore, seven different HPV gen-
otypes were detected, among which six types (16, 18, 31,
33, 51 and 56) were carcinogenic, or “high risk geno-
types” and one genotype (HPV-66) was “probably car-
cinogenic.” Table 1 shows the detected HPV genotypes.
The median age of the HPV-positive women was 25 years
(min = 24, max = 42 years). All had been married when
they were less than 24 years old. None had a history of
multiple sexual partners, previous sexually transmitted
disease, or tobacco smoking. All had been pregnant, and
the median of parity was (min = 0, max = 3). Four out of
five HPV-positive women had a history of oral contra-
ceptive use. Only one woman had ever had a Pap test.
Two HPV-positive women had low socioeconomic sta-
tus. However, none of the HPV-positive women was
illiterate.
Cytopathology
The Pap tests of 40 (5.0%) women showed epithelial cell
abnormalities. Atypical squamous cells of undetermined
significance (ASCUS) and cervical intraepithelial neopla-
sia (CINI) were found in 32 (4.0%) and eight (1.0%)topathological findings of Iranian women according to
lation-based study Clinic-based study*
n = 799 n= 200
5 (0.63%) 11 (5.5%)
9 (1.12%) 9 (4.5%)
2 4
18, 31, 33, 51, 56 16, 18
66 53
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with HPV were detected in nine (1.12%) women. How-
ever, two were found to be HPV-positive by PCR. On
the other hand, three women who were identified as
HPV DNA positive by the PCR method were negative
for HPV infection when they were evaluated by the Pap
test.
Discussion
The overall prevalence of HPV infection among the
women in our study is lower than that observed world-
wide. To the best of our knowledge, this is the first
population-based study in the south part of Iran to investi-
gate the prevalence rate of HPV infection in this region.
The prevalence rate of HPV infection differs notably
according to geographical region [1]. The worldwide
prevalence of HPV infection in women with normal cer-
vical cytology was estimated to be 11.7% [20]. Based on
molecular epidemiologic evidence among asymptomatic
women in the general population, the prevalence of
HPV infection was estimated to be in the range of 2-
44% [21]. In a comprehensive review, Seoud et al.
reported that HPV was found in 1.5-13% of the general
population of the Middle East and the Persian Gulf
countries [22]. Our study shows that the prevalence of
HPV infection in southern Iranian women is among the
lowest in the world and Middle Eastern countries. This
prevalence rate is much lower than that reported for the
Persian Gulf region (4-11%) [22].
Comparisons of HPV prevalence by geographical area
or country are generally hampered by the heterogeneity
in laboratory assays employed for HPV infection detec-
tion, the population included (women with normal cy-
tology, population-based surveys, or women in routine
screening programs), and the variation in HPV types
detected [1].
Although a few population-based studies on the preva-
lence of HPV infection in the Persian Gulf and the Mid-
dle Eastern countries could be found in the medical
literature, the low prevalence of oncogenic HPV infec-
tion in Iran (the current study) and Kuwait (1.39%) [23]
compared with the rest of the world, may reflect differ-
ences in sexual behavior across the Persian Gulf region.
In both countries, the majority of women have their first
experience of sexual intercourse during married life and
have one husband in a lifetime [23]. However, questions
related to sexual and reproductive behavior are consid-
ered taboo in Muslim countries.
The present community study did not confirm our
previous study on reporting HPV prevalence among
women in southern Iran [12] despite of using the same
protocols and techniques. However, there is a difference
between their target population (population-based study
versus gynecology clinic-based study).In the previous study, we determined the prevalence
of various HPV genotypes among women who had rou-
tine Pap smear tests in a university gynecology clinic
(Table 1). In that study, the prevalence of various HPV
genotypes was 11 (5.5%) in 200 samples [12]. This preva-
lence rate was similar to those reported from various
studies in Iran. All previous studies in Iran regarding the
prevalence of HPV infection were performed on women
attending gynaecological clinics for routine screening
programs and examinations [11-13]. HPV DNA was
identified in 5.7% women who were admitted to different
hospitals and gynecological clinics in Tehran [13]. Safaei
et al. [14] reported positive HPV findings in 5.5% of
women who were examined at two gynecological clinics
in Shiraz, a city in the southwest of Iran with a popula-
tion very similar to the population in the current study.
Therefore, it seems that the prevalence of HPV infection
was very similar in different gynecological clinics in Iran
and was comparable to other geographical areas in
Muslim and Middle Eastern countries.
Although, in a recent population based study on geni-
tal HPV by Khodakarami and her colleagues [15] among
2342 women in one of the densely populated suburb of
Theran the prevalence of HPV infection was 7.8% which
is different from our present finding. The number of
participant as well as the differences between their com-
munities might be the reason of obsereved difference.
Indeed, they have used different techniques compared to
ours with different sensitivity such as DNA extraction
using magnetic beads and liquid based cytology and even
different type of sampling and it could be also consid-
ered as the other factor that would explain the difference
between our data and their findings.
Similarly, the observed prevalence of HPV high and
low risk types in cervical samples taken in a population-
based study in Italy was lower than those in studies that
were performed on women undergoing voluntary cer-
vical cancer screening in gynaecological clinics [24,25].
Notably, sampling in gynaecological clinics or voluntary
screening programs may select women who are more
sexually active than the general population or those with
abnormal cytological results. These women usually seek
more cervical examinations than women with normal
cytology [25]. In contrast, the design of a population-
based study mandates a better coverage of the general
population [26].
Based on the present study nine samples were
detected HPV positive by Pap smear test meanwhile two
of them were approved by HPV DNA PCR test. More-
over, there are other three HPV DNA positive samples
among the Pap smear test negatives. This observation
could be because of the lack of specificity of Pap smear
test for HPV detection.
Eghbali et al. Virology Journal 2012, 9:194 Page 5 of 6
http://www.virologyj.com/content/9/1/194Previous studies have indicated a significant geo-
graphic variation in the pattern of oncogenic HPV types.
HPV 16 was the most commonly identified type in most
countries of the world [27]. In the current study and our
previous clinic-based study, HPV 16 was the most preva-
lent type, and HPV 18 was the second most prevalent
oncogenic HPV type. These findings are consistent with
studies on the Extended Middle East and North Africa
(EMENA) [22]. It has been estimated that 32% of about
291 million women worldwide who are carriers of HPV
are infected with HPV 16 or HPV 18, or both [20]. HPV
types 58 and 52 play a more prominent role in cervical
cancer in all regions of Asia—except India and Iran—
than in other parts of the world [8,28-30]. We also did
not find these oncogenic HPV types in our both studies.
A comparison of our results with some similar studies
in Muslim and Middle Eastern countries [31,32] showed
a similar prevalence of epithelial abnormalities in Pap
smears. In the current study, the Pap tests of 40 (5.0%)
women showed epithelial cell abnormalities. Overall, the
majority of women had negative results of both HPV
DNA and Pap tests. Also, weakness of cytopathological
detection of genital HPV was noted by Khodakarami
et al. [15]. Therfore, re-screening of those women can be
done at three years [33]. The extended period of re-
screening for women with negative results for both tests
is considered an advantage for HPV DNA testing [3]. In-
deed, the type of used device for cytopathology specimen
collection (wooden Ayre spatula) might be a reason for
poor quality of detection compared to the plastic cyto-
brush that used for PCR test.
Our study has several limitations. The small sample
size of this study in a population-based setting may have
underestimated the prevalence of HPV infection in the
general population. Indeed, this limitation may decrease
the chance of detection of different genotypes with lower
prevalence such as HPV-42 and HPV-6 compared to the
prevalent genotypes. In addition, the participation rate
in the current study was 87.60%. The non-responders
may produce a selection bias. It is probable that the
non-responders may be at higher risk of HPV acquisi-
tion. However, the major reasons for non-participation
were having to work, anxiety and doing Pap smear
examination before the invitation time. The cross-
sectional design of the study did not provide the oppor-
tunity to examine trends over time. We also did not
evaluate risk factors for the acquisition and persistence
of oncogenic HPV types. We also did not have informa-
tion on the husband’s sexual behavior and therefore po-
tential confounding effects cannot be evaluated in our
study. Because of the low prevalence of HPV infection in
the current study, we cannot evaluate the prevalence of
oncogenic HPV types among women with epithelial ab-
normalities in cervical cytological examinations.Moreover, The small number of HPV positive cases in
our study precludes any age-specific incidence rate.
Thus, larger population-based studies in different
regions are needed to eliminate the drawbacks of our
study and to determine the accurate prevalence of HPV
infection among women in Iran. Based on the very low
prevalence of HPV infection in this study, there are cur-
rently no indicative data to support use of HPV vaccine in
southern Iranian women. Since cervical cancer ranks as
12th most frequent cancer among women in Iran [16],
screening with HPV plus Pap tests every 2 or 3 years may
save additional years of life at reasonable costs.
Conclusions
In conclusion, in a population-based study, the preva-
lence of HPV infection among southern Iranian women
was very low. Indeed, the prevalence of HPV was signifi-
cantly lower than we reported in our clinic-based study.
In other words, gynaecological clinic-based data gener-
ally overestimate HPV prevalence. Therefore, estimates
of prevalence based on clinic-based data should be
adjusted downward according to population-based sur-
vey estimates [25]. Undoubtedly, estimation of HPV in-
fection based on population-based surveys would
provide valuable data particularly to intoduce the strat-
egies for the screening of cervical cancer and HPV vac-
cination in Iran.
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